Outcome of Board meeting held on May 23, 2026.
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Divis Laboratories reported strong full-year FY2025-26 results. Standalone revenue grew 13% to Rs 10,388 crore from Rs 9,198 crore, while consolidated revenue rose 12.8% to Rs 10,560 crore. Standalone PAT increased 18% to Rs 2,607 crore (from Rs 2,209 crore) and consolidated PAT grew 17.2% to Rs 2,568 crore. The board recommended a dividend of Rs 30 per share (1500% on face value Rs 2). An exceptional charge of Rs 74 crore was recognized due to the implementation of new Indian Labour Codes, which management classified as non-recurring. Foreign exchange gains boosted other income significantly at Rs 210 crore for the year. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements. Capital expenditure continued at elevated levels with payments for PPE at Rs 2,520 crore.
Strong financial performance with ~18% PAT growth driven by robust API/nutraceutical demand. The clean audit opinion and no going-concern issues are reassuring. The exceptional labour code charge of Rs 74 crore is one-time in nature and does not affect underlying business strength.